Current Appointments & Affiliations
Associate Professor of Medicine
·
2021 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2011 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
A Breakthrough From China in a Rare Form of Kidney Cancer.
Journal Article JAMA Oncol · August 14, 2025 Full text Link to item CiteUpdated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer.
Journal Article Prostate Cancer Prostatic Dis · June 2025 Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We pr ... Full text Link to item CiteIntensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.
Journal Article Eur Urol Oncol · April 2025 BACKGROUND AND OBJECTIVE: Androgen deprivation therapy (ADT) with salvage radiation therapy (RT) improves survival for patients with prostate-specific antigen (PSA) recurrence after radical prostatectomy (RP) for prostate cancer (PC), but many patients suf ... Full text Link to item CiteRecent Grants
A Randomized Phase 2 Trial of Nivolumab, Relatlimab plus Ipilimumab vs. Nivolumab plus Ipilimumab in first-line advanced renal cell carcinoma (RCC)
Clinical TrialPrincipal Investigator · Awarded by The University of Texas MD Anderson Cancer Center · 2025 - 2030A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2025 - 2030A Phase I/IIa theranostic study of 64Cu-SAR-BBN and 67CuSAR-BBN for identification and treatment of RPRexpressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA617
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2024 - 2028View All Grants
Education, Training & Certifications
Tulane University ·
2004
M.D.